
The study investigated whether the benefits of empagliflozin on left ventricular mass (LVM) regression varied among South Asian and non-South Asian individuals with type 2 diabetes and coronary artery disease. Despite baseline differences, the study found no substantial disparity in LVM regression between the two groups over the 6-month trial period. The study suggests that empagliflozin's impact on LVM is consistent across ethnicities in individuals with type 2 diabetes and coronary artery disease.
Like
Save
Share